Literature DB >> 16931688

Imaging pain modulation by subanesthetic S-(+)-ketamine.

Till Sprenger1, Michael Valet, Ralph Woltmann, Claus Zimmer, Rainer Freynhagen, Eberhard F Kochs, Thomas R Tölle, Klaus J Wagner.   

Abstract

Little is known about the effects of low-dose S-(+)-ketamine on the cerebral processing of pain. We investigated the effects of subanesthetic IV S-(+)-ketamine doses on the perception of experimental painful heat stimuli. Healthy volunteers were evaluated with functional magnetic resonance imaging (fMRI) while receiving the painful stimuli in conjunction with placebo and increasing doses (0.05, 0.1, 0.15 mg x kg(-1) x h(-1)) of ketamine infusion. Vital variables were monitored and all subjects rated pain intensity and unpleasantness on a numerical rating scale. Alterations in consciousness were measured using a psycho-behavioral questionnaire. Pain unpleasantness declined as ketamine dosage was increased (55.1% decrease, placebo versus 0.15 mg x kg(-1) x h(-1) ketamine). Pain intensity ratings also decreased with increasing ketamine dosage but to a lesser extent (23.1% decrease). During placebo administration, a typical pain activation network (thalamus, insula, cingulate, and prefrontal cortex) was found, whereas decreased pain perception with ketamine was associated with a dose-dependent reduction of pain-induced cerebral activations. Analysis of the dose-dependent ketamine effects on pain processing showed a decreasing activation of the secondary somatosensory cortex (S2), insula and anterior cingulate cortex. This part of the anterior cingulate cortex (midcingulate cortex) has been linked with the affective pain component that underlines the potency of ketamine in modulating affective pain processing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931688     DOI: 10.1213/01.ane.0000231635.14872.40

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  19 in total

Review 1.  Current understanding of the neuropathophysiology of pain in chronic pancreatitis.

Authors:  Amporn Atsawarungruangkit; Supot Pongprasobchai
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

Review 2.  Role of neuroimaging in analgesic drug development.

Authors:  Jane Lawrence; Sean C Mackey
Journal:  Drugs R D       Date:  2008

Review 3.  Unraveling the mystery of pain in chronic pancreatitis.

Authors:  Pankaj Jay Pasricha
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-01-24       Impact factor: 46.802

4.  Brain activity associated with pain, hyperalgesia and allodynia: an ALE meta-analysis.

Authors:  Stefan Lanz; Frank Seifert; Christian Maihöfner
Journal:  J Neural Transm (Vienna)       Date:  2011-03-04       Impact factor: 3.575

Review 5.  [Studies on cerebral processing of pain using functional imaging : Somatosensory, emotional, cognitive, autonomic and motor aspects].

Authors:  M Valet; T Sprenger; T R Tölle
Journal:  Schmerz       Date:  2010-04       Impact factor: 1.107

Review 6.  Central sensitization: implications for the diagnosis and treatment of pain.

Authors:  Clifford J Woolf
Journal:  Pain       Date:  2010-10-18       Impact factor: 6.961

Review 7.  The pain imaging revolution: advancing pain into the 21st century.

Authors:  David Borsook; Simona Sava; Lino Becerra
Journal:  Neuroscientist       Date:  2010-04       Impact factor: 7.519

Review 8.  Analgo-sedation of patients with burns outside the operating room.

Authors:  Cesare Gregoretti; Daniela Decaroli; Quirino Piacevoli; Alice Mistretta; Nicoletta Barzaghi; Nicola Luxardo; Irene Tosetti; Luisa Tedeschi; Laura Burbi; Paolo Navalesi; Fabio Azzeri
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 9.  Ketamine in pain management.

Authors:  Jan Persson
Journal:  CNS Neurosci Ther       Date:  2013-05-11       Impact factor: 5.243

10.  Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings).

Authors:  Georges Mion; Thierry Villevieille
Journal:  CNS Neurosci Ther       Date:  2013-04-10       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.